23 completed, 7 terminated, 3 withdrawn, 1 active not recruiting. 22 Phase 2, 7 Phase 1, 3 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 14, Terminated 5, Withdrawn 3 |
| Phase 1 | 7 | Completed 6, Terminated 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Not applicable | 1 | Terminated 1 |
Follow Gastrinoma: new trials by email Literature Review of Gastrinoma trials Research Report on Gastrinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs 177Lu-DOTATOC - Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Withdrawn | British Columbia Cancer Agency | 2023-01-15 | 2023-02-21 | |
| DOTATOC PET/CT for Imaging NET Patients 68Ga-DOTATOC PET/CT, 18F-FDG PET/CT - Neuroendocrine Tumors, Insulinoma | Active not recruiting | British Columbia Cancer Agency | 800 | 2018-07-11 | 2026-05-12 | |
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors regorafenib, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Completed | University of Southern California | 3 | 2016-08-16 | 2021-12-15 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Everolimus - Estrogen Receptor-positive Breast Cancer, Gastrinoma | Phase 2 | Terminated | Emory University | 2 | 2014-11-01 | 2017-02-03 |
| Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors dovitinib lactate, pharmacological study, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2014-10-01 | 2017-07-19 | |
| Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery everolimus, placebo - Gastrinoma, Glucagonoma | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 2 | 2014-04-10 | 2023-06-29 |
| Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors temozolomide, capecitabine - Gastrinoma, Glucagonoma | Phase 2 | Completed | ECOG-ACRIN Cancer Research Group | 144 | 2013-08-08 | 2026-09-29 |
| Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Capecitabine, Temozolomide, Bevacizumab - Gastrinoma, Glucagonoma | Phase 2 | Completed | Shaheen Shagufta | 20 | 2012-12-01 | 2024-02-06 |
| Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors PVA microporous hydrospheres/doxorubicin hydrochloride - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Not applicable | Terminated | Yale University | 13 | 2009-02-01 | 2017-08-25 |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors AMG 706, octreotide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Eastern Cooperative Oncology Group | 46 | 2008-11-07 | 2023-07-05 |
| Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Fentanyl sublingual spray, Placebo - Cancer | Phase 3 | Completed | INSYS Therapeutics Inc | 130 | 2007-10-01 | 2014-03-05 |
| Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors questionnaire administration, quality-of-life assessment - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Unknown | National Cancer Institute (NCI) | 408 | 2006-10-01 | 2013-10-29 | |
| Cinacalcet to Treat Familial Primary Hyperparathyroidism Parathyroid hormone testing, Serum calcium testing - Hypercalcemia, Familial Primary Hyperparathyroidism | Phase 3 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 25 | 2006-05-09 | 2017-07-02 |
| Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors capecitabine, cisplatin, streptozocin - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 84 | 2005-08-01 | 2013-08-07 |
| Capecitabine and Temozolomide for Neuroendocrine Cancers Capecitabine, Temozolomide - Neuroendocrine Tumors | Phase 2 | Completed | Columbia University | 41 | 2005-08-01 | 2016-07-25 |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors bevacizumab, 5-fluorouracil, leucovorin - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 / Phase 3 | Terminated | University of California, San Francisco | 36 | 2005-06-08 | 2023-05-22 |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors sorafenib tosylate - Gastrinoma, Glucagonoma | Phase 2 | Completed | National Cancer Institute (NCI) | 93 | 2005-06-01 | 2014-11-17 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors everolimus, vatalanib, pharmacological study - Gastrinoma, Glucagonoma | Phase 1 | Completed | Mayo Clinic | 96 | 2004-12-01 | 2024-08-21 |
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery fluorouracil, irinotecan hydrochloride, leucovorin calcium - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Federation Francophone de Cancerologie Digestive | 20 | 2004-05-01 | 2016-05-30 |
| Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors romidepsin, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 25 | 2004-03-01 | 2013-06-04 |
Showing 20 of 35. Sign in to see all of them.
Insulinoma (30) · Glucagonoma (27) · Somatostatinoma (27) · Carcinoma, Islet Cell (25) · Vipoma (19) · Adenoma, Islet Cell (14) · Neoplasms (12) · Carcinoma, Medullary (8) · Neuroendocrine Tumors (7) · Pheochromocytoma (7) · Carcinoma, Renal Cell (6) · Pancreatic Neoplasms (6) · Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (5)
Adenocarcinoma (35) · Digestive System Diseases (35) · Digestive System Neoplasms (35) · Endocrine Gland Neoplasms (35) · Endocrine System Diseases (35) · Neoplasms by Histologic Type (35) · Neoplasms by Site (35) · Neoplasms, Glandular and Epithelial (35) · Pancreatic Diseases (35) · Carcinoma (34) · Neoplasms, Germ Cell and Embryonal (32) · Neuroectodermal Tumors (32) · Adenoma (31) · Carcinoma, Neuroendocrine (31) · Pancreatic Neoplasms (29)
Capecitabine (4) · Everolimus (3) · Fluorouracil (3) · Leucovorin (3) · Octreotide (3) · Temozolomide (3) · Bevacizumab (2) · Doxorubicin (2) · Oxaliplatin (2) · Streptozocin (2) · Trastuzumab (2) · vatalanib (2) · 177Lu-octreotide, DOTA(0)-Tyr(3)- (1) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · 90Y-octreotide, DOTA-Tyr(3)- (1)
National Cancer Institute (NCI) (6) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4) · British Columbia Cancer Agency (2) · ECOG-ACRIN Cancer Research Group (2) · Eastern Cooperative Oncology Group (2) · Memorial Sloan Kettering Cancer Center (2) · Novartis Pharmaceuticals (2) · Yale University (2) · Academic and Community Cancer Research United (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Columbia University (1) · Emory University (1) · Federation Francophone de Cancerologie Digestive (1) · INSYS Therapeutics Inc (1) · Mayo Clinic (1)
United States (28) · Canada (2) · United Kingdom (2) · Denmark (1) · Germany (1) · Greece (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Sweden (1)
Francois Benard, MD (2) · Leonard B. Saltz, MD (2) · Mary Mulcahy, MD (2) · Timothy Hobday (2) · Anthony W. Tolcher, MD (1) · Emily Bergsland (1) · Emily K. Bergsland, MD (1) · Guillaume Cadiot (1) · Jeffrey F. Geschwind, MD (1) · John K. Ramage, MD (1) · John R. Murren, MD (1) · Julian R. Molina, M.D., Ph.D. (1) · Kyle Holen, MD (1) · Larry Dillaha, MD (1) · Larry K. Kvols, MD (1)
PMID 20847174, PMID 21831734, PMID 22480131, PMID 22722717, PMID 27020837, PMID 29853660, PMID 36260828
N01CM62205 (2), U01CA076576 (2), U10CA021115 (2), P30CA014089 (1), U10CA023318 (1), U10CA180820 (1)